Form 4 for CUE Cue Biopharma, Inc.
Accepted 2021-11-15 00:00:00 ET · period of report 2021-11-11 · accession 0000899243-21-044603 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-15 | 2021-11-11 | CUE | Suri Anish | Pres, CSO | S - Sale+OE | $15.07 | -20.0K | 94.0K | -18% | -$301.4K |
| D | 2021-11-15 | 2021-11-11 | CUE | Suri Anish | Pres, CSO | M - OptEx | $6.42 | +20.0K | 114.0K | +21% | +$128.4K |
| D | 2021-11-15 | 2021-11-11 | CUE | Suri Anish | Pres, CSO | M - OptEx | $0.00 | -20.0K | 105.0K | -16% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-11 | S | D | 20,000 | $15.07 | 94,038 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.29, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. |
| 2 | Common | Common Stock | 2021-11-11 | M | A | 20,000 | $6.42 | 114,038 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2021-11-11 | M | D | 20,000 | $0.00 | 105,000 | D | $6.42 · — to 2029-03-06 | 20,000 Common Stock | (F3) The option vests in eight equal semi-annual installments beginning September 6, 2019. |